Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.52 |
| ▸ | EBP | Q15125 | 2/20 | 0.52 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21023241 | 1.00 | SIGMAR1 (0.52) | SIGMAR1EBPCACNA1GSLC6A2SLC6A4 | |
| SCHEMBL5239794 | 0.92 | SIGMAR1 (0.60) | SIGMAR1EBPCCR3 | |
| SCHEMBL6786053 | 0.88 | SIGMAR1 (0.45) | SIGMAR1EBPCACNA1GSLC6A3MC4R | |
| SCHEMBL5237846 | 0.88 | SIGMAR1 (0.60) | SIGMAR1EBPSLC6A3MEN1KMT2A | |
| SCHEMBL14431859 | 0.87 | CCR3 (0.54) | SIGMAR1EBPCYP2D6RAB9AKCNH2 | |
| SCHEMBL5751414 | 0.85 | CCR1 (0.45) | SIGMAR1EBPCACNA1GSLC6A4SLC6A3 | |
| SCHEMBL5751875 | 0.85 | HTR1A (0.54) | SIGMAR1CACNA1GMEN1ALDH1A1LMNA | |
| SCHEMBL5240018 | 0.85 | RAB9A (0.52) | SIGMAR1EBPRAB9ACCR1OPRM1 | |
| SCHEMBL5749643 | 0.85 | POLB (0.46) | SIGMAR1EBPCACNA1GSLC6A4SLC6A3 | |
| SCHEMBL2866236 | 0.84 | CACNA1B (0.52) | SIGMAR1CACNA1GMEN1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230165812-A1 | NOCICEPTOR NEURONS CONTROL CANCER IMMUNOSURVEILLANCE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-06-01 | — | — | US | disclosed |
| US-20230165812-A1 | NOCICEPTOR NEURONS CONTROL CANCER IMMUNOSURVEILLANCE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-06-01 | — | — | US | disclosed |
| US-20220016046-A1 | PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI-INFLAMMATORY AGENTS | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2022-01-20 | — | — | US | disclosed |
| US-20210290561-A1 | PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI-INFLAMMATORY AGENTS | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2021-09-23 | — | — | US | disclosed |
| US-10729664-B2 | Permanently charged sodium and calcium channel blockers as anti-inflammatory agents | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2020-08-04 | — | — | US | disclosed |
| US-20190216747-A1 | PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI-INFLAMMATORY AGENTS | CHILDREN'S MEDICAL CENTER CORPORATION | 2019-07-18 | — | — | US | disclosed |
| EP-2995303-A1 | PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI-INFLAMMATORY AGENTS | President and Fellows of Harvard College (US) | 2016-03-16 | — | — | EP | disclosed |
| US-20120172429-A1 | PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI- INFLAMMATORY AGENTS | THE GENERAL HOSPITAL CORPORATION | 2012-07-05 | — | — | US | disclosed |
| US-20120172429-A1 | PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI- INFLAMMATORY AGENTS | THE GENERAL HOSPITAL CORPORATION | 2012-07-05 | — | — | US | disclosed |
| WO-2011006073-A1 | PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI-INFLAMMATORY AGENTS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2011-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172429-A1 | PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI- INFLAMMATORY AGENTS | TRPV1, CACNA1B, ORAI1 | SIGMAR1 1477/4885EBP 2369/4885CACNA1G 9/4885 |
| US-10729664-B2 | Permanently charged sodium and calcium channel blockers as anti-inflammatory agents | TRPV1, CACNA1B, ORAI1 | SIGMAR1 1477/4885EBP 2369/4885CACNA1G 9/4885 |
| US-20230165812-A1 | NOCICEPTOR NEURONS CONTROL CANCER IMMUNOSURVEILLANCE | OPRL1, MRGPRX1, RAMP1 | SIGMAR1 411/4885EBP 4385/4885CACNA1G 47/4885 |
| US-20190216747-A1 | PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI-INFLAMMATORY AGENTS | TRPV1, CACNA1B, ORAI1 | SIGMAR1 1477/4885EBP 2369/4885CACNA1G 9/4885 |
| US-20210290561-A1 | PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI-INFLAMMATORY AGENTS | TRPV1, CACNA1B, ORAI1 | SIGMAR1 1477/4885EBP 2369/4885CACNA1G 9/4885 |
| US-20220016046-A1 | PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI-INFLAMMATORY AGENTS | CACNA1B, TRPV1, ORAI1 | SIGMAR1 1504/4885EBP 2294/4885CACNA1G 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.